Plasmodium falciparum spermidine synthase inhibition results in unique perturbation-specific effects observed on transcript, protein and metabolite levels.
BACKGROUND
Plasmodium falciparum, the causative agent of severe human malaria, has evolved to become resistant to previously successful antimalarial chemotherapies, most notably chloroquine and the antifolates. The prevalence of resistant strains has necessitated the discovery and development of new chemical entities with novel modes-of-action. Although much effort has been invested in the creation of analogues based on existing drugs and the screening of chemical and natural compound libraries, a crucial shortcoming in current Plasmodial drug discovery efforts remains the lack of an extensive set of novel, validated drug targets. A requirement of these targets (or the pathways in which they function) is that they prove essential for parasite survival. The polyamine biosynthetic pathway, responsible for the metabolism of highly abundant amines crucial for parasite growth, proliferation and differentiation, is currently under investigation as an antimalarial target. Chemotherapeutic strategies targeting this pathway have been successfully utilized for the treatment of Trypanosomes causing West African sleeping sickness. In order to further evaluate polyamine depletion as possible antimalarial intervention, the consequences of inhibiting P. falciparum spermidine synthase (PfSpdSyn) were examined on a morphological, transcriptomic, proteomic and metabolic level.


RESULTS
Morphological analysis of P. falciparum 3D7 following application of the PfSpdSyn inhibitor cyclohexylamine confirmed that parasite development was completely arrested at the early trophozoite stage. This is in contrast to untreated parasites which progressed to late trophozoites at comparable time points. Global gene expression analyses confirmed a transcriptional arrest in the parasite. Several of the differentially expressed genes mapped to the polyamine biosynthetic and associated metabolic pathways. Differential expression of corresponding parasite proteins involved in polyamine biosynthesis was also observed. Most notably, uridine phosphorylase, adenosine deaminase, lysine decarboxylase (LDC) and S-adenosylmethionine synthetase were differentially expressed at the transcript and/or protein level. Several genes in associated metabolic pathways (purine metabolism and various methyltransferases) were also affected. The specific nature of the perturbation was additionally reflected by changes in polyamine metabolite levels.


CONCLUSIONS
This study details the malaria parasite's response to PfSpdSyn inhibition on the transcriptomic, proteomic and metabolic levels. The results corroborate and significantly expand previous functional genomics studies relating to polyamine depletion in this parasite. Moreover, they confirm the role of transcriptional regulation in P. falciparum, particularly in this pathway. The findings promote this essential pathway as a target for antimalarial chemotherapeutic intervention strategies.
Becker
John V W
JV
CSIR Biosciences, PO Box 395, Pretoria, 0001, South Africa.
Mtwisha
Linda
L
Crampton
Bridget G
BG
Stoychev
Stoyan
S
van Brummelen
Anna C
AC
Reeksting
Shaun
S
Louw
Abraham I
AI
Birkholtz
Lyn-Marie
LM
Mancama
Dalu T
DT
D003514:Cyclohexylamines / Q000494:pharmacology; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects*; D053858:Metabolic Networks and Pathways; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism*; D011073:Polyamines / Q000378:metabolism; D015800:Protozoan Proteins / Q000378:metabolism; D011436:Spermidine Synthase / Q000037:antagonists & inhibitors*
D003514:Cyclohexylamines; D011073:Polyamines; D015800:Protozoan Proteins; D011436:Spermidine Synthase
J Biol Chem. 2009 Feb 13;284(7):4635-46
19073607
Bioorg Med Chem. 2007 Feb 15;15(4):1628-37
17196392
J Chromatogr B Biomed Sci Appl. 2000 Aug 18;745(2):431-7
11043761
Genome Res. 2004 Aug;14(8):1548-54
15256513
Biotechniques. 2003 Feb;34(2):374-8
12613259
Biol Chem. 2008 Feb;389(2):111-25
18163886
J Bacteriol. 2000 Dec;182(23):6732-41
11073919
J Parasitol. 1979 Jun;65(3):418-20
383936
BMC Genomics. 2008 Aug 18;9:388
18706115
Plant Physiol. 1986 Oct;82(2):607-9
16665078
Proteomics. 2005 May;5(7):1849-58
15832369
Mol Microbiol. 2002 Oct;46(1):179-90
12366841
Biochem J. 1987 Feb 15;242(1):221-6
3109383
Mol Microbiol. 2003 Nov;50(4):1229-39
14622411
Mol Biochem Parasitol. 2005 Aug;142(2):224-36
15913804
Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8393-8
18541913
Bioinformatics. 2004 Dec 12;20(18):3656-8
15247094
Infect Immun. 2007 Apr;75(4):2012-25
17283083
Mol Cell Biochem. 1995 Mar 23;144(2):125-9
7623783
Trends Parasitol. 2001 May;17(5):242-9
11323309
Parasitol Res. 2001 Nov;87(11):963-72
11728024
J Chromatogr. 1988 Apr 8;426(1):41-54
3384880
J Biol Chem. 2000 Mar 17;275(11):8097-102
10713131
Genome Biol. 2007;8(7):R134
17612404
J Cell Mol Med. 2005 Jul-Sep;9(3):623-42
16202210
Mol Microbiol. 2004 May;52(4):1187-99
15130134
Genome Res. 2004 Nov;14(11):2308-18
15520293
Curr Drug Targets. 2003 Oct;4(7):537-64
14535654
Biochem J. 2003 Nov 15;376(Pt 1):1-14
13678416
Biochem J. 1986 Mar 1;234(2):249-62
3087344
Proc Natl Acad Sci U S A. 1989 Jan;86(2):651-5
2463635
Mem Inst Oswaldo Cruz. 2000 Mar-Apr;95(2):231-5
10733745
Am J Trop Med Hyg. 2007 Aug;77(2):201-8
17690387
Biochem J. 1988 Jan 1;249(1):33-6
3124824
BMC Genomics. 2004 Mar 09;5(1):20
15113400
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
9843981
PLoS Pathog. 2008 Nov;4(11):e1000214
19023412
Amino Acids. 2010 Feb;38(2):633-44
19997948
Biochem Biophys Res Commun. 2000 May 19;271(3):559-64
10814501
PLoS Pathog. 2008 Aug 08;4(8):e1000118
18688278
PLoS Biol. 2003 Oct;1(1):E5
12929205
BMC Genomics. 2008 Feb 28;9:105
18307768
Science. 2006 Aug 4;313(5787):667-9
16888139
Mol Biochem Parasitol. 2004 Jan;133(1):125-9
14668019
Parasitol Res. 2003 Dec;91(6):508-16
14530966